GENFIT is a late-stage clinical biopharmaceutical company focused on the discovery and development of drug candidates and diagnostic solutions targeting metabolic and liver-related diseases. Co. is engaged in the field of nuclear receptor-based drug discovery. Co. is evaluating its primary drug candidate, elafibranor, as a potential treatment for primary biliary cholangitis. Co. is also conducting pre-clinical research, notably on NTZ, which could be repositioned for the treatment of liver fibrosis. The GNFT stock yearly return is shown above.
The yearly return on the GNFT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GNFT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|